The London Movement Disorders Centre (LMDC) is a clinical and research unit with many students and clinical and research fellows. The laboratory conducts innovative research work from animal-based neuroscience to therapeutics in patients. The research work from this laboratory has been recognized by both academia and industry. We currently have strong research partnerships with Abbvie, Allergan, Boston Scientific, Medtronic, and Merz Pharmaceuticals for the application of our innovative work to their products. The innovative work in our laboratory has led to the foundation of a spin-off company MDDT Inc three years ago, which has been successful in R&D development of our technology for applications in patients. Our four focuses are:

1. Patient Care: To provide outstanding clinical care through local and outreach programs abroad
2. Clinical Research: To advance our extensive research program by collaborating with other centres
3. Education and Training: To deliver world-class training to future movement disorder specialists
4. Technology Commercialization: To quickly move from research to treatment for our patients now

For educational apps movement disorder specialists, please check out ToxinMed.com and MovDis.com to learn more.

Since 2008, the LondonMDC has been awarded and maintains the prestigious designation of Centers of Excellence by the Parkinson's Foundation. As a National Parkinson Foundation Center of Excellence, we pursue the highest standards of clinical care by creating a network of professionals from a variety of disciplines to treat our patients. Our innovative research initiatives improve the quality of life for individuals living with Parkinson disease and their care partners. 

 

Dr. Mandar S. Jog, MD, FRCPC

Mandar S. Jog, MD, FRCPC, is the Director of the National Parkinson Foundation Centre of Excellence in Parkinson Disease and Movement Disorders Program at London Health Sciences Centre and a Professor of Neurology at Western University, both in London, Ontario, Canada. He is also one of the Associate Directors of the Lawson Health Research Institute.

He trained in Neurology in Toronto and completed a fellowship in movement disorders with Dr. Anthony Lang. This was followed by a 4-year post-doctoral fellowship in Computational Neuroscience at the Massachusetts Institute of Technology (MIT) in Boston, Massachusetts, under Dr. Ann Graybiel and a visiting professorship at Stanford Research Institute (SRI Inc.) in California.

In addition to a large clinical practice Dr. Jog supervises many masters, PhD and post-doctoral research and clinical fellows in his laboratory. With 6 patents and 4 provisional patents for innovative technology he is the co-founder of Medtrode Inc., MDDT Inc., and founder of ManJog Enterprises Limited. Dr. Jog's research attempts to probe the structure and function of the basal ganglia and their role in movement disorders.

His research projects on which he has published more than 300 papers and given over 300 national and international presentations focus on:

  • Technology for the assessment and treatment of movement disorders
  • Speech
  • Gait, balance, and posture and planning and spinal cord stimulation
  • Animal models and electrophysiology of the basal ganglia
  • Human intraoperative electrophysiological recording
  • Computational and mathematical modeling of information processing in the brain

Dr. Jog travels internationally to conduct workshops and courses, along with many speaking engagements. Dr. Jog has also published two books including one on the mathematical basis of information processing in the brain. In addition, Dr. Jog participates in many national and international clinical trials for new treatments for movement disorders. Dr. Jog was awarded the Dean’s Award for Excellence in Research (2012), Queens Diamond Jubilee award (2013) and has been awarded the Faculty Scholar Award (2014) for exemplary research, teaching and service, the President’s Award for Innovation (2014) from the London Health Sciences Centre and the Strategic Research Fund Award (2015) from the Lawson Health Research Institute. He was awarded the Lawson Innovation award in 2018.